Preclinical Immunogenicity and Efficacy of a Multiple Antigen-Presenting System (MAPS(TM)) SARS-CoV-2 Vaccine

Despite the remarkable success of SARS-CoV-2 vaccines, the rise of variants, some of which are more resistant to the effects of vaccination, highlights the potential need for additional COVID-19 vaccines. We used the Multiple Antigen-Presenting System (MAPS) technology, in which proteins are present...

Descripción completa

Detalles Bibliográficos
Autores principales: Cieslewicz, Brian, Makrinos, Daniel, Burke, Heidi, Bree, Dara, Haridas, Renuka, Tonkiss, Ian, Bartsch, Yannic, Alter, Galit, Malley, Richard, Besin, Gilles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9317729/
https://www.ncbi.nlm.nih.gov/pubmed/35891233
http://dx.doi.org/10.3390/vaccines10071069

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9317729/
https://www.ncbi.nlm.nih.gov/pubmed/35891233
http://dx.doi.org/10.3390/vaccines10071069

Ejemplares similares